Thermostat Coolant Engine Housing 902-693 Dorman Car & Truck Thermostats & Parts

  1. Home
  2. Thermostat Coolant Engine Housing 902-693 Dorman
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Engine Coolant Thermostat Housing Dorman 902-693
Condition: New Warranty: Other
Flange Length: 2.55 In. Quantity: 1
Bolt Hole Center To Bolt Hole Center: 2.835 In.; 1.66 In.; 3.65 In. SKU: DOR:902693




Manufacturer Part Number:


Gasket or Seal Included: Yes
Bolt Hole Quantity: 3 Thermostat Included: Yes
Thermostat Opening Temperature: 180 Deg. F. Inside Diameter: 0.515 In.; 0.664 In.; 0.588 In.; 1.165 In.;
Bleeder Hole: No Gasket Type: Gasket
Flange Thickness: 0.5 In. Outlet Port Quantity: 4
Material: Metal Mounting Hardware Included: No
Flange Width: 4.14 In. Grade Type: Regular
Product Description: Integrated Thermostat Housing Assembly UPC:

Does not apply

published on tue nov 09 2021

Thermostat Coolant Engine Housing 902-693 Dorman Car & Truck Thermostats & Parts

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Thermostat Coolant Engine Housing 902-693 Dorman Car & Truck Thermostats & Parts

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.